Kaposi's Sarcoma - Epidemiology Forecast to 2028

"Kaposi's Sarcoma - Pipeline Insight, 2019” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Kaposi's Sarcoma development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Kaposi's Sarcoma
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Kaposi's Sarcoma
The report assesses the active Kaposi's Sarcoma pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Kaposi's Sarcoma
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Kaposi's Sarcoma
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Kaposi's Sarcoma
• The report also covers the dormant and discontinued pipeline projects related to the Kaposi's Sarcoma

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Kaposi's Sarcoma to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Kaposi's Sarcoma therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

1. Report Introduction
2. Kaposi's Sarcoma Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Kaposi's Sarcoma in 2016
2.2. Patient Share Distribution of Kaposi's Sarcoma in 2028
3. Disease Background and Overview: Kaposi's Sarcoma
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Kaposi's Sarcoma in 7MM
4.3. Total Prevalent/ Incident Patient Population of Kaposi's Sarcoma in 7MM – By Countries
5. Epidemiology of Kaposi's Sarcoma by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Kaposi's Sarcoma
5.1.3. Sub-Type Specific cases of the Kaposi's Sarcoma *
5.1.4. Sex- Specific Cases of the Kaposi's Sarcoma *
5.1.5. Diagnosed Cases of the Kaposi's Sarcoma
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Kaposi's Sarcoma
5.4.3. Sub-Type Specific cases of the Kaposi's Sarcoma *
5.4.4. Sex- Specific Cases of the Kaposi's Sarcoma *
5.4.5. Diagnosed Cases of the Kaposi's Sarcoma
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Kaposi's Sarcoma
5.5.3. Sub-Type Specific cases of the Kaposi's Sarcoma *
5.5.4. Sex- Specific Cases of the Kaposi's Sarcoma *
5.5.5. Diagnosed Cases of the Kaposi's Sarcoma
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Kaposi's Sarcoma
5.6.3. Sub-Type Specific cases of the Kaposi's Sarcoma *
5.6.4. Sex- Specific Cases of the Kaposi's Sarcoma *
5.6.5. Diagnosed Cases of the Kaposi's Sarcoma
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Kaposi's Sarcoma
5.7.3. Sub-Type Specific cases of the Kaposi's Sarcoma *
5.7.4. Sex- Specific Cases of the Kaposi's Sarcoma *
5.7.5. Diagnosed Cases of the Kaposi's Sarcoma
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Kaposi's Sarcoma
5.8.3. Sub-Type Specific cases of the Kaposi's Sarcoma *
5.8.4. Sex- Specific Cases of the Kaposi's Sarcoma *
5.8.5. Diagnosed Cases of the Kaposi's Sarcoma
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Kaposi's Sarcoma
5.9.3. Sub-Type Specific cases of the Kaposi's Sarcoma *
5.9.4. Sex- Specific Cases of the Kaposi's Sarcoma *
5.9.5. Diagnosed Cases of the Kaposi's Sarcoma
6. Unmet Needs of the Kaposi's Sarcoma
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight

List of Table:

Table 1: Total Prevalent/Incident Cases of the Kaposi's Sarcoma in 7MM
Table 2: Total Prevalent/Incident Cases of the Kaposi's Sarcoma in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Kaposi's Sarcoma in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Kaposi's Sarcoma in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Kaposi's Sarcoma in United States (2016-2028)*
Table 6: Diagnosed Cases of the Kaposi's Sarcoma in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Kaposi's Sarcoma in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Kaposi's Sarcoma in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Kaposi's Sarcoma in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Kaposi's Sarcoma in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Kaposi's Sarcoma in France (2016-2028)
Table 12: Sub-Type Specific cases of the Kaposi's Sarcoma in France (2016-2028) *
Table 13: Sex- Specific Cases of the Kaposi's Sarcoma in France (2016-2028) *
Table 14: Diagnosed Cases of the Kaposi's Sarcoma in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Kaposi's Sarcoma in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Kaposi's Sarcoma in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Kaposi's Sarcoma in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Kaposi's Sarcoma in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Kaposi's Sarcoma in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Kaposi's Sarcoma in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Kaposi's Sarcoma in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Kaposi's Sarcoma in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Kaposi's Sarcoma in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Kaposi's Sarcoma in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Kaposi's Sarcoma in UK (2016-2028) *
Table 26: Diagnosed Cases of the Kaposi's Sarcoma in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Kaposi's Sarcoma in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Kaposi's Sarcoma in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Kaposi's Sarcoma in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Kaposi's Sarcoma in Japan (2016-2028)

List of Figure:

Figure 1: Total Prevalent/Incident Cases of the Kaposi's Sarcoma in 7MM
Figure 2: Total Prevalent/Incident Cases of the Kaposi's Sarcoma in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Kaposi's Sarcoma in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Kaposi's Sarcoma in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Kaposi's Sarcoma in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Kaposi's Sarcoma in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Kaposi's Sarcoma in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Kaposi's Sarcoma in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Kaposi's Sarcoma in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Kaposi's Sarcoma in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Kaposi's Sarcoma in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Kaposi's Sarcoma in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Kaposi's Sarcoma in France (2016-2028) *
Figure 14: Diagnosed Cases of the Kaposi's Sarcoma in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Kaposi's Sarcoma in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Kaposi's Sarcoma in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Kaposi's Sarcoma in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Kaposi's Sarcoma in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Kaposi's Sarcoma in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Kaposi's Sarcoma in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Kaposi's Sarcoma in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Kaposi's Sarcoma in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Kaposi's Sarcoma in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Kaposi's Sarcoma in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Kaposi's Sarcoma in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Kaposi's Sarcoma in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Kaposi's Sarcoma in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Kaposi's Sarcoma in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Kaposi's Sarcoma in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Kaposi's Sarcoma in Japan (2016-2028)